Unlabelled: OBJECTIVES. This work was designed to study melatonin (M) production levels in duodenal ulcer (DU) patients in the exacerbation and remission stages and in DU patients with a different course of DU in the exacerbation and remission stages.
Methods: DU patients (15 men aged 20 to 45, mean age 34,2 +/- 1,1 years) were studied. The control group included 11 healthy volunteers (men aged 20-45, mean age 32,5 +/- 1,4 years). M was measured by RIA-method using H(3)-labeled M in daily urine collected at 3-hour intervals (8 portions per day). Mathematical processing was carried out using ANOVA, Student's t-test, and cosinor analysis. Differences at p< or = 0,05 were considered to be significant.
Results: A strong disturbance of M secretion in DU patients both in the exacerbation and remission stages and a direct correlation between the degree of M production disturbance and severity of clinical course of DU were revealed.
Conclusion: The obtained results suggest that circadian rhythms of M production are altered in DU patients. M was supposed to be involved in the pathogenesis of DU.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies.
Rev Cardiovasc Med
December 2024
Department of Biomedical Science, School of Health and Life Sciences, Teesside University, TS1 3BX Middlesbrough, UK.
Diabetes mellitus (DM) affects 537 million people as of 2021, and is projected to rise to 783 million by 2045. This positions DM as the ninth leading cause of death globally. Among DM patients, cardiovascular disease (CVD) is the primary cause of morbidity and mortality.
View Article and Find Full Text PDFClinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A analysis of RELIght study.
Allergy Asthma Proc
January 2025
2nd Respiratory Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function.
View Article and Find Full Text PDFTransient Psychotic Relapse Following COVID-19 in a Stable Schizophrenia Patient on Paliperidone Palmitate: A Case Report.
Cureus
November 2024
Psychiatry, Maudsley Health, Al Amal Psychiatric Hospital, Dubai, ARE.
Schizophrenia is a chronic psychiatric disorder marked by severe disturbances in thought, perception, and behavior. Long-acting injectable (LAI) antipsychotics, such as paliperidone, are widely used to promote sustained remission and ensure medication adherence, especially in patients prone to relapse. However, the COVID-19 pandemic has introduced unique challenges, with studies indicating that infections like COVID-19 may exacerbate psychiatric symptoms through neuroinflammatory pathways.
View Article and Find Full Text PDFLong-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review.
Clin Exp Rheumatol
December 2024
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Objectives: To clarify the impact of sarilumab (SAR) on the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).
Methods: We conducted a retrospective review of all consecutive RA patients from the KEIO-RA cohort who visited our institution between 2018 and 2024 and received SAR treatment. Patients were followed for 24 months from the initiation of SAR.
The effect of benralizumab on inflammation in severe asthma: a real-life analysis.
Ther Adv Respir Dis
December 2024
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!